JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.

This research has direct clinical implications for AML, particularly in patients with KMT2A-rearranged and NPM1-mutated leukemia, who are currently being treated with menin inhibitors. By ...

Discover three undervalued biotech stocks with strong assets, solid cash reserves, and major catalysts ahead. Click for the ...

JPMorgan raised the firm’s price target on Syndax (SNDX) to $41 from $39 and keeps an Overweight rating on the shares after having surveyed 23 ...

Actinium Pharma inks research pact with Memorial Sloan Kettering to support further clinical expansion of Actimab-A's backbone therapy strategy: New York Saturday, March 22, 2025, ...

Actinium Pharmaceuticals (ATNM) has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to expand ...